The neurobiology of the Prader-Willi phenotype of fragile X syndrome
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and autism, caused by a CGG expansion to greater than 200 repeats in the promoter region of FMR1 on the bottom of the X chromosome. A subgroup of individuals with FXS experience hyperphagia, lack of satiation after meals and severe obesity, this subgroup is referred to have the Prader-Willi phenotype of FXS. Prader-Willi syndrome is one of the most common genetic severe obesity disorders known and it is caused by the lack of the paternal 15q11-13 region. Affected individuals suffer from hyperphagia, lack of satiation, intellectual disability, and behavioral problems. Children with fragile X syndrome Prader-Willi phenotye and those with Prader Willi syndrome have clinical and molecular similarities reviewed here which will impact new treatment options for both disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dawson, G., Jones, E. J. H., Merkle, K., Venema, K., Lowy, R., Faja, S., Kamara, D., Murias, M., Greenson, J., Winter, J., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.08.018 · Cited by 799 · cited 1×
“developmental and social outcome in addition to normalization of the EEG abnormalities compared to those treated with community behavioral interventions (28).”
BackgroundAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Self-citationHypothalamic Control of Feeding and Self-Stimulation
Hoebel, B. G., & Teitelbaum, P. (1962) · Science · doi:10.1126/science.135.3501.375 · Cited by 389 · cited 1×
“The lateral hypothalamus (LH) is a critical modulator of feeding (12,13).”
BackgroundLong-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes
Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131901 · Cited by 334
Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Self-citationSchenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.-L., & Giangrande, A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00354-4 · Cited by 316
Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 1×
“Minocycline has been studied in children with FXS and has demonstrated some efficacy so it is often utilized clinically (35,36).”
BackgroundSelf-citationDe Rubeis, S., Pasciuto, E., Li, K. W., Fernández, E., Di Marino, D., Buzzi, A., Ostroff, L. E., Klann, E., Zwartkruis, F. J. T., Komiyama, N. H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.039 · Cited by 296
Chai, J.-H., Locke, D. P., Greally, J. M., Knoll, J. H. M., Ohta, T., Dunai, J., Yavor, A., Eichler, E. E., & Nicholls, R. D. (2003) · The American Journal of Human Genetics · doi:10.1086/378816 · Cited by 218
Pathania, M., Davenport, E. C., Muir, J., Sheehan, D. F., López-Doménech, G., & Kittler, J. T. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.16 · Cited by 189 · cited 2×
“Neurons from CYFIP1 haploinsufficient animals have smaller and less complex dendritic branching both in vitro and in vivo (23).”
BackgroundThe Prader-Willi phenotype of fragile X syndrome
Nowicki, S. T., Tassone, F., Ono, M. Y., Ferranti, J., Croquette, M. F., Goodlin-Jones, B., & Hagerman, R. J. (2007) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/01.dbp.0000267563.18952.c9 · Cited by 174
Self-citationLuo, T., Nocon, A., Fry, J., Sherban, A., Rui, X., Jiang, B., Xu, X. J., Han, J., Yan, Y., Yang, Q., et al. (2016) · Diabetes · doi:10.2337/db15-1122 · Cited by 172
McLennan, Y., Polussa, J., Tassone, F., & Hagerman, R. (2011) · Current Genomics · doi:10.2174/138920211795677886 · Cited by 160
Self-citationEffects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143
Tauber, M., Mantoulan, C., Copet, P., Jauregui, J., Demeer, G., Diene, G., Rogé, B., Laurier, V., Ehlinger, V., Arnaud, C., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-47 · Cited by 117
Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders
Francis, S. M., Sagar, A., Levin-Decanini, T., Liu, W., Carter, C. S., & Jacob, S. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.021 · Cited by 101
Monyak, R. E., Emerson, D., Schoenfeld, B. P., Zheng, X., Chambers, D. B., Rosenfelt, C., Langer, S., Hinchey, P., Choi, C. H., McDonald, T. V., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.51 · Cited by 100
Indah Winarni, T., Chonchaiya, W., Adams, E., Au, J., Mu, Y., Rivera, S. M., Nguyen, D. V., & Hagerman, R. J. (2012) · Autism Research and Treatment · doi:10.1155/2012/104317 · Cited by 52
Self-citationJin, J., Gu, H., Anders, N. M., Ren, T., Jiang, M., Tao, M., Peng, Q., Rudek, M. A., & Duan, W. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8412-z · Cited by 50
Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
Ying, M., Maruschak, N., Mansur, R., Carvalho, A., Cha, D., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130205514 · Cited by 29
Cited by
Metformin as targeted treatment in fragile X syndrome
Dy, A. B. C., Tassone, F., Eldeeb, M., Salcedo‐Arellano, M. J., Tartaglia, N., & Hagerman, R. (2018) · Clinical Genetics · doi:10.1111/cge.13039 · Cited by 124
Self-citationMetformin treatment in young children with fragile X syndrome
Biag, H. M. B., Potter, L. A., Wilkins, V., Afzal, S., Rosvall, A., Salcedo‐Arellano, M. J., Rajaratnam, A., Manzano‐Nunez, R., Schneider, A., Tassone, F., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.956 · Cited by 68
Self-citationProtic, D., Aydin, E. Y., Tassone, F., Tan, M. M., Hagerman, R. J., & Schneider, A. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.745 · Cited by 34
Self-citationBabbs, R. K., Beierle, J. A., Ruan, Q. T., Kelliher, J. C., Chen, M. M., Feng, A. X., Kirkpatrick, S. L., Benitez, F. A., Rodriguez, F. A., Pierre, J. J., et al. (2019) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.119.400470 · Cited by 26
Metadata
- Authors
- Muzar, Z., Lozano, R., Kolevzon, A., & Hagerman, R. J.
- Venue
- Intractable & Rare Diseases Research
- Publisher
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
- Published
- 2016
- Volume
- 5
- Issue
- 4
- Pages
- 255-261
- ISSN
- 2186-361X (ISSN-L)
- 2186-3644
- OpenAlex
- W2551315476
- Cited by
- 22
- References
- 20
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.